氧压调节纳米配方,用于改善低氧瘤的光动力疗法
Yihenew Simegniew Birhan1,2, Chia-Yen Hsu1, Hsiu-Ping Yu1
1Department of Chemistry, National Chung Hsing University, Taichung, 402, Taiwan.
Materials today. Bio
|March 17, 2025
概括
这项研究开发了新型聚化物纳米粒子 (CPLA-NPs) 来提供氧气,增强固体瘤的光动力学治疗 (PDT). 这些纳米粒子有效地克服瘤缺氧,提高癌症治疗效率.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 光动力学疗法 光动力学疗法
背景情况:
- 光动力疗法 (PDT) 的疗效受到固体瘤中低氧水平的限制.
- 高压氧 (HBO) 或产生氧的纳米酶是增强PDT的潜在策略.
- 开发高效的氧气输送系统对于治疗缺氧瘤至关重要.
研究的目的:
- 为了合成和表征4臂聚化物 (CPLA) 合物用于输送氧气.
- 评估基于CPLA的纳米颗粒 (Air-CPLA-NPs) 在克服增强PDT的瘤缺氧方面的有效性.
- 研究空气-CPLA-NP与PDT结合的体外和体内抗癌作用.
主要方法:
- 通过环开聚合 (ROP) 合成4臂CPLA结合物.
- 组装的CPLA结合成单分散的纳米粒子 (空气-CPLA-NP).
- 评估细胞内化,反应性氧物种 (ROS) 生成,细胞毒性和in vivo瘤生长抑制.
主要成果:
- 空气-CPLA-NP成功地将分子氧输送到缺氧瘤区域.
- 对Air-CPLA-NPs的光照射产生了显著的细胞内ROS和单点氧 (O2).
- 在体外研究显示了剂量依赖的细胞毒性,而在体内研究显示了显著的瘤生长抑制.
结论:
- 在低氧瘤中,CPLA-NP充当有效的氧气穿器,克服氧气屏障.
- 开发的Air-CPLA-NP显著提高了PDT的疗效.
- 这种纳米平台有望改善PDT在固体瘤治疗中的临床应用.
相关概念视频
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K